中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

代谢相关脂肪性肝病患儿外周血黏膜相关恒定T淋巴细胞的频率、表型及功能改变

姜涛 欧阳文献 谭艳芳 康桢 李双杰

引用本文:
Citation:

代谢相关脂肪性肝病患儿外周血黏膜相关恒定T淋巴细胞的频率、表型及功能改变

DOI: 10.3969/j.issn.1001-5256.2023.03.012
基金项目: 

湖南省卫生计生委科研课题 (20200695)

伦理学声明:本研究方案于2020年4月30日经由湖南省儿童医院伦理委员会审批,批号:HCHLL-2020-38,所纳入患儿家属均签署知情同意书。
利益冲突声明:本研究不存在研究者、伦理委员会成员、受试者监护人以及与公开研究成果有关的利益冲突。
作者贡献声明:姜涛和谭艳芳负责课题设计,资料分析,撰写论文;康桢参与收集数据,修改论文;欧阳文献和李双杰负责拟定写作思路,指导撰写文章并最后定稿。
详细信息
    通信作者:

    李双杰,lesjie62@vip.sina.com (ORCID:0000-0002-3792-6793)

Changes in the frequency, phenotype, and function of mucosal-associated invariant T lymphocytes in peripheral blood of children with metabolic associated fatty liver disease

Research funding: 

Scientific Research Project of Health and Family Planning Commission of Hunan Province (20200695)

More Information
  • 摘要:   目的  探讨代谢相关脂肪性肝病(MAFLD)患儿外周血黏膜相关恒定T(MAIT)淋巴细胞的变化及其临床意义。  方法  选取2022年3月—2022年5月在湖南省儿童医院就诊的18例MAFLD患儿(MAFLD组)及同期20例正常对照儿童(对照组),采集外周血,流式细胞仪检测MAIT淋巴细胞(CD3+CD161+TCRVα7.2+细胞)及其不同MAIT淋巴细胞亚型(CD4+CD8-MAIT淋巴细胞、CD4-CD8-MAIT淋巴细胞、CD4-CD8+MAIT淋巴细胞和CD4+CD8+MAIT淋巴细胞)比例,表达PD-1、CD69、穿孔素、CD107α、CXCR3、CXCR6和CCR6的MAIT淋巴细胞比例,分析MAIT淋巴细胞频率与肝脏炎症、脂肪含量和纤维化程度的相关性。符合正态分布的计量资料两组间比较采用t检验;非正态分布计量资料两组间比较采用Mann-Whitney U检验;相关性分析采用Spearman相关分析法。  结果  与对照组相比,MAFLD组中外周血MAIT淋巴细胞比例及表达PD-1、CD69、CD107α、CXCR3、CXCR6和CCR6的MAIT淋巴细胞比例均明显升高(P值均<0.05);MAIT淋巴细胞亚型中CD4+CD8-MAIT淋巴细胞、CD4+CD8+MAIT淋巴细胞所占MAIT淋巴细胞比例明显升高(P值均<0.001),CD4-CD8+MAIT淋巴细胞所占MAIT淋巴细胞比例降低(P<0.001);CD4+CD8+MAIT淋巴细胞(r=-0.474,P=0.047)和CD107α阳性MAIT淋巴细胞比例(r=-0.550,P=0.018)与ALT呈负相关。  结论  外周血MAIT淋巴细胞向肝脏趋化聚集,在儿童MAFLD肝脏炎症中发挥保护作用。

     

  • 表  1  两组患儿临床资料比较

    Table  1.   The comparation of clinical data between the two groups

    指标 MAFLD组(n=18) 对照组(n=20) 统计值 P
    男/女(例) 10/8 11/9
    年龄(岁) 10.65(8.44~11.87) 9.00(7.40~11.25) Z=-1.083 0.279
    ALT(U/L) 37.30(25.08~157.53) 13.65(11.75~17.00) Z=-4.474 <0.001
    AST(U/L) 29.95(26.08~62.70) 20.95(18.90~24.23) Z=-3.304 0.001
    WBC(×109/L) 7.31±2.56 7.00±1.50 t=0.937 0.355
    中性粒细胞(×109/L) 4.47(3.36~5.18) 3.62(2.77~3.97) Z=-2.222 0.026
    淋巴细胞(×109/L) 2.76(2.38~3.11) 2.44(1.82~2.91) Z=-1.608 0.112
    下载: 导出CSV

    表  2  两组患儿外周血MAIT淋巴细胞及各亚组MAIT淋巴细胞频率比较

    Table  2.   The comparation of the peripheral blood MAIT lymphocytes and subtypes between the two groups

    指标 MAFLD组(n=18) 对照组(n=20) Z P
    MAIT淋巴细胞(%) 2.98(1.83~5.99) 0.29(0.09~0.69) -4.765 <0.001
    CD4+CD8-MAIT淋巴细胞(%) 13.75(3.28~30.33) 0.38(0~1.55) -3.703 <0.001
    CD4-CD8-MAIT淋巴细胞(%) 26.45(1.03~47.03) 31.25(24.05~50.33) 0.254 >0.05
    CD4-CD8+MAIT淋巴细胞(%) 9.20(1.16~16.80) 43.65(29.65~64.98) -3.876 <0.001
    CD4+CD8+MAIT淋巴细胞(%) 25.65(14.78~84.95) 9.36(6.04~22.45) -2.675 <0.001
    下载: 导出CSV

    表  3  两组患儿外周血MAIT淋巴细胞表型和功能的差异

    Table  3.   Differences in phenotype and function of peripheral blood MAIT lymphocytes between the two groups

    指标 MAFLD组(n=18) 对照组(n=20) Z P
    PD-1(%) 21.80(8.38~51.70) 4.43(2.07~11.29) -3.334 0.001
    CD69(%) 56.00(28.93~68.35) 18.90(13.23~31.18) -2.646 0.008
    穿孔素(%) 9.32(4.53~18.80) 4.16(1.35~9.53) -1.827 0.068
    CD107α(%) 45.20(26.03~59.03) 10.95(6.80~17.18) -3.172 0.002
    CXCR3(%) 87.35(80.08~96.03) 44.80(32.93~53.00) -4.678 <0.001
    CXCR6(%) 30.40(8.24~54.90) 6.02(3.27~21.58) -2.939 0.003
    CCR6(%) 26.80(13.03~77.70) 4.94(3.32~17.13) -2.749 0.006
    下载: 导出CSV

    表  4  MAFLD组患儿外周血MAIT细胞频率与肝脏炎症、脂肪含量和纤维化程度相关性分析

    Table  4.   Correlation analysis between the frequency of MAIT lymphocytes in peripheral blood and the degree of liver inflammation, fat content, and fibrosis in children with MAFLD

    项目 ALT AST 弹性值 脂肪肝参数
    MAIT淋巴细胞
      r 0.041 -1.050 0.064 0.112
      P 0.871 0.677 0.801 0.660
    CD4+CD8-MAIT淋巴细胞
      r -0.305 -0.330 -0.303 -0.272
      P 0.218 0.181 0.221 0.275
    CD4-CD8+MAIT淋巴细胞
      r 0.140 -0.130 -0.047 0.228
      P 0.580 0.606 0.854 0.363
    CD4+CD8+MAIT淋巴细胞
      r -0.474 -0.436 -0.347 -0.115
      P 0.047 0.071 0.158 0.650
    CD107α阳性MAIT淋巴细胞
      r -0.550 -0.334 -0.201 -0.168
      P 0.018 0.176 0.432 0.504
    下载: 导出CSV
  • [1] JIN R, WANG XX, LIU F, et al. Research advances in pharmacotherapy for nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2022, 38(7): 1634-1640. DOI: 10.3969/j.issn.1001-5256.2022.07.033.

    靳睿, 王晓晓, 刘峰, 等. 非酒精性脂肪性肝病的药物治疗进展[J]. 临床肝胆病杂志, 2022, 38(7): 1634-1640. DOI: 10.3969/j.issn.1001-5256.2022.07.033.
    [2] ESLAM M, ALKHOURI N, VAJRO P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement[J]. Lancet Gastroenterol Hepatol, 2021, 6(10): 864-873. DOI: 10.1016/S2468-1253(21)00183-7.
    [3] ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209. DOI: 10.1016/j.jhep.2020.03.039.
    [4] FLISIAK-JACKIEWICZ M, LEBENSZTEJN DM. Update on pathogenesis, diagnostics and therapy of nonalcoholic fatty liver disease in children[J]. Clin Exp Hepatol, 2019, 5(1): 11-21. DOI: 10.5114/ceh.2019.83152.
    [5] CZAJA AJ. Incorporating mucosal-associated invariant T cells into the pathogenesis of chronic liver disease[J]. World J Gastroenterol, 2021, 27 (25): 3705-3733. DOI: 10.3748/wjg.v27.i25.3705.
    [6] LEGOUX F, BELLET D, DAVIAUD C, et al. Microbial metabolites control the thymic development of mucosal-associated invariant T cells[J]. Science, 2019, 366(6464): 494-499. DOI: 10.1126/science.aaw2719.
    [7] HEGDE P, WEISS E, PARADIS V, et al. Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver[J]. Nat Commun, 2018, 9(1): 2146. DOI: 10.1038/s41467-018-04450-y.
    [8] LI Y, HUANG B, JIANG X, et al. Mucosalassociated invariant T cells improve nonalcoholic fatty liver disease through regulating macrophage polarization[J]. Front Immunol, 2018, 9: 1994. DOI: 10.3389/fimmu.2018.01994.
    [9] DIEDRICH T, KUMMER S, GALANTE A, et al. Characterization of the immune cell landscape of patients with NAFLD[J]. PLoS One, 2020, 15(3): e0230307. DOI: 10.1371/journal.pone.0230307.
    [10] HE SL, LI SJ, LIU M, et al. Study on the diagnostic value of transient elastography, APRI and FIB-4 for liver fibrosis in children with non-alcoholic fatty liver disease[J]. Chin J Hepatol, 2022, 30(1): 81-86. DOI: 10.3760/cma.j.cn501113-20210105-00007.

    何舒丽, 李双杰, 刘敏, 等. 瞬时弹性成像技术、APRI及FIB-4对儿童非酒精性脂肪性肝病肝纤维化诊断价值的研究[J]. 中华肝脏病杂志, 2022, 30(1): 81-86. DOI: 10.3760/cma.j.cn501113-20210105-00007.
    [11] LIU M, ZHENG X, QIU J, et al. Diagnostic value of CAP in children with nonalcoholic fatty liver disease[J]. J Clin Res, 2021, 38(3): 343-348. DOI: 10.3969/j.issn.1671-7171.2021.03.006.

    刘敏, 郑曦, 仇君, 等. CAP对儿童非酒精性脂肪性肝病的诊断价值研究[J]. 医学临床研究, 2021, 38(3): 343-348. DOI: 10.3969/j.issn.1671-7171.2021.03.006.
    [12] CAROLAN E, TOBIN LM, MANGAN BA, et al. Altered distribution and increased IL-17 production by mucosal-associated invariant T cells in adult and childhood obesity[J]. J Immunol, 2015, 194(12): 5775-5780. DOI: 10.4049/jimmunol.1402945.
    [13] MAGALHAES I, PINGRIS K, POITOU C, et al. Mucosal-associated invariant T cell alterations in obese and type 2 diabetic patients[J]. J Clin Invest, 2015, 125(4): 1752-1762. DOI: 10.1172/JCI78941.
    [14] van HERCK MA, WEYLER J, KWANTEN WJ, et al. The differential roles of T cells in non-alcoholic fatty liver disease and obesity[J]. Front Immunol, 2019, 10: 82. DOI: 10.3389/fimmu.2019.00082.
    [15] LIU J, NAN H, BRUTKIEWICZ RR, et al. Sex discrepancy in the reduction of mucosal-associated invariant T cells caused by obesity[J]. Immun Inflamm Dis, 2021, 9(1): 299-309. DOI: 10.1002/iid3.393.
    [16] BERGIN R, KINLEN D, KEDIA-MEHTA N, et al. Mucosal-associated invariant T cells are associated with insulin resistance in childhood obesity, and disrupt insulin signalling via IL-17[J]. Diabetologia, 2022, 65(6): 1012-1017. DOI: 10.1007/s00125-022-05682-w.
    [17] NAIMIMOHASSES S, O'GORMAN P, WRIGHT C, et al. Differential effects of dietary versus exercise intervention on intrahepatic MAIT cells and histological features of NAFLD[J]. Nutrients, 2022, 14(11): 2198. DOI: 10.3390/nu14112198.
    [18] KOAY HF, GHERARDIN NA, ENDERS A, et al. A three-stage intrathymic development pathway for the mucosal-associated invariant T cell lineage[J]. Nat Immunol, 2016, 17(11): 1300-1311. DOI: 10.1038/ni.3565.
    [19] ZENG F, ZHANG Y, HAN X, et al. Predicting non-alcoholic fatty liver disease progression and immune deregulations by specific gene expression patterns[J]. Front Immunol, 2020, 11: 609900. DOI: 10.3389/fimmu.2020.609900.
  • 加载中
表(4)
计量
  • 文章访问数:  412
  • HTML全文浏览量:  130
  • PDF下载量:  66
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-10-21
  • 录用日期:  2022-12-06
  • 出版日期:  2023-03-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回